(17 days)
Not Found
No
The document describes a quality control material for laboratory tests, not a device that processes data or images using AI/ML.
No
The device is a quality control material intended for use in clinical laboratory quality assurance programs, not for treating any medical condition.
No
Explanation: The device is a quality control material intended to assist in controlling the accuracy and precision of laboratory cardiac marker procedures, not to diagnose a patient's condition.
No
The device is described as a "quality control material" and "Liquid Tri-Level Cardiac Control," indicating it is a physical substance used for calibration and quality assurance, not a software application.
Based on the provided information, the device "Dade TRU-Liquid Cardiac Control" is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it's for "use as an assayed quality control material in clinical laboratory quality assurance programs and to assist in the control of accuracy and precision of a laboratory's cardiac marker procedures." This clearly indicates it's used in vitro (outside the body) to evaluate the performance of diagnostic tests.
- Device Description: It's described as "Quality Control Material (Assayed and Unassayed)." Quality control materials are a fundamental component of IVD testing.
- Intended User / Care Setting: It's intended for use in a "clinical laboratory," which is the typical setting for IVD testing.
- Predicate Device: The mention of a predicate device (K961828; Liquichek Cardiac Markers Control) which is also a quality control material for cardiac markers, further supports its classification as an IVD. Predicate devices are used in the regulatory process for IVDs.
Therefore, all the key indicators point to this device being an In Vitro Diagnostic.
N/A
Intended Use / Indications for Use
Dade TRU-Liquid Cardiac Control is intended for use as an assayed quality control material in clinical laboratory quality assurance programs and to assist in the control of accuracy and precision of a laboratory's cardiac marker procedures.
Product codes
JJT
Device Description
Not Found
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Not Found
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.1660 Quality control material (assayed and unassayed).
(a)
Identification. A quality control material (assayed and unassayed) for clinical chemistry is a device intended for medical purposes for use in a test system to estimate test precision and to detect systematic analytical deviations that may arise from reagent or analytical instrument variation. A quality control material (assayed and unassayed) may be used for proficiency testing in interlaboratory surveys. This generic type of device includes controls (assayed and unassayed) for blood gases, electrolytes, enzymes, multianalytes (all kinds), single (specified) analytes, or urinalysis controls.(b)
Classification. Class I (general controls). Except when intended for use in donor screening tests, quality control materials (assayed and unassayed) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
0
17173974
NOV - 6 1997
510(k) Summary of Safety and Effectiveness Information Dade® TRU-Liquid™ Cardiac Control October 17, 1997
Dade International Inc. 2173 N.W. 99th Avenue Miami, FL 33172 Contact Person: Betty Hernandez-Labadie at (305)392-5618, or by facsimile at (305)392-5622.
| Trade or Proprietary Name: | Dade® TRU-Liquid™ Cardiac Control
Levels 1,2 and 3. | |
|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|
| Common or Usual Name: | Liquid Tri-Level Cardiac Control | |
| Classification Name: | Quality Control Material (Assayed and Unassayed) | |
| Registration Number: | Manufacturer
Dade International Inc.
2173 N.W. 99th Avenue
Miami, FL 33172
(formerly at 9750 N.W. 25 Street, Miami, FL 33172)
Dade International Inc.
1851 Delaware Parkway
Miami, Florida 33125 | 1025506
1017272 |
The proposed Dade® TRU-Liquid™ Cardiac Control is substantially equivalent in terms of intended use and safety and effectiveness to the Liquichek Cardiac Markers Control manufactured by Bio-Rad Laboratories, previously cleared under Document Control No., K961828.
1
Image /page/1/Picture/1 description: The image shows the seal of the U.S. Department of Health & Human Services. The seal features a stylized caduceus, a symbol often associated with medicine and healthcare. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" are arranged in a circular pattern around the caduceus. The seal is black and white.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Betty Hernandez-Labadie . Senior Regulatory Specialist Dade International Inc. 2173 N.W. 99 Avenue Miami, Florida 33172
Re : K973974 Dade® TRU-Liquid™ Cardiac Control Levels 1,2, and 3 Requlatory Class: I Product Code: JJT October 17, 1997 Dated: Received: October 20, 1997
Dear Ms. Hernandez-Labadie:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions The general controls provisions of the Act of the Act. include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major requlations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory In addition, FDA may publish further announcements action. concerning your device in the Federal Register. Please note:
this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
2
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling requlation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours,
Steven Litman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
3
| 510(k) Number (if known): | --------- |
|---|---|
| --------------------------- | ----------- |
Dade TRU-Liquid Cardiac Control Device Name:
Indications For Use:
Dade TRU-Liquid Cardiac Control is intended for use as an assayed quality control material in clinical laboratory quality assurance programs and to assist in the control of accuracy and precision of a laboratory's cardiac marker procedures.
(PLEASE DO NOT WITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Patricell. Bernkarót
(Division Sign-Off) (for Awm)
Division of Clinical Laboratory evices
510(k) Number K973974
::
Prescription Use (Per 21 CFR 801.109)
OR
Over-The-Counter Use
(Optional Format 1-2-96)